NUVB

NEW YORK, July 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the underwriters have exercised in full their over-allotment option (the "Greenshoe Exercise") to purchase an additional $37.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2032 (the "Notes").  The aggregate principal amount of Notes sold in the offering was $287.5 million, inclusive of the $37.5 million aggregate principal amount of Notes issued pursuant to the Greenshoe Exercise.

According to a Form 4 filing, a Nuvation Bio executive reported selling 125,000 Class A shares for a total value of $753,000 on June 23, 2026. This transaction represented 79.32% of Markel Stacy's direct Class A holdings, reducing the direct position to 32,591 shares, though she also retains significant exposure through stock options.

FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.

NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing of its underwritten offering (the "Offering") of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032 (the "Notes"). The aggregate principal amount of the Offering was increased from the previously announced offering size of $200.0 million.

NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced its intent to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the "Notes") in an underwritten offering (the "Offering"). Nuvation Bio also intends to grant the underwriters of the Notes a right to purchase, exercisable within 30 days of the date of the prospectus supplement relating to the Offering, up to an additional $30.0 million aggregate principal amount of Notes, solely to cover over-allotments, if any.

I initiate coverage of Nuvation Bio with a Moderate Buy, citing undervaluation based on two value-driving oncology assets. NUVB's fundamentals hinge on Ibtrozi (taletrectinib), a next-gen ROS1 inhibitor now commercial, and safusidenib, a late-stage mutant IDH1 inhibitor. My sum-of-the-parts analysis yields a $5.6/share fair value, with further upside from M&A potential, re-rating anchored on recent M&A activity, and milestone payments.

NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 9:55 a.m.

88% of TRUST-II patients reported improved or stable quality of life at first assessment, with the majority sustaining that benefit throughout treatment Cognitive function scores improved or remained stable throughout the course of treatment with IBTROZI IBTROZI provided rapid relief from burdensome symptoms, including cough and shortness of breath NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new patient-reported outcomes data from the pivotal TRUST-II study of IBTROZI® (taletrectinib) in patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The new data will be presented on Sunday, May 31 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026.

Nuvation Bio Inc. (NUVB) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Nuvation Bio Inc. (NUVB) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript